The U.S. Patent and Trademark Office has issued the first U.S. Patent to Achillion resulting from its complement factor D research program.​

“Achillion’s aim is to establish a broad patent portfolio for its complement program. With the granting of this first patent we are pleased that the USPTO has confirmed that Achillion possesses a multitude of patentable complement factor D inhibitors,” commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. “As a leader in AP (alternative pathway) biology, we are proud to have been the first to clinically demonstrate, in healthy volunteers, the ability to suppress AP activity following oral dosing of our complement factor D inhibitor, ACH-4471.​”